Christophe Schilling, Ph.D.  |  Chief Executive Officer Bio

Christophe Schilling, Ph.D.

Christophe founded Genomatica in 1998. Since being named CEO in May 2009, he has led Genomatica to widespread recognition as a leader in industrial biotech, with a commercialized first process, top-tier licensees, strong investors - and an unrivaled string of awards for engineering (Kirkpatrick), science (EPA Presidential Green Chemistry), industry leadership (voted #1 Hottest three years in a row by Biofuels Digest), and company culture (The Scientist as a Best Place to Work). Christophe frequently speaks on industry trends at major conferences, and serves as a member of the World Economic Forum Global Agenda Council on Biotechnology.

Christophe holds a Ph.D. in bioengineering from the University of California, San Diego. He received a B.S. in biomedical engineering from Duke University and was honored as a Distinguished Young Alumnus in 2010.

Mark Burk, Ph.D.  |  Executive Vice President and Chief Technology Officer Bio

Mark Burk, Ph.D.

Mark has served as our Executive Vice President and Chief Technology Officer since September 2006. From November 2000 to July 2006, Mark was Senior Vice President of Research and Development at Diversa Corporation. Before that, from October 1996 to November 2000, Mark held a director position at Chiroscience Pharmaceuticals, a U.K.-based pharmaceuticals and technology company. From July 1993 to August 1996, Mark served on the faculty of the Department of Chemistry and Biochemistry at Duke University. From June 1988 to July 1993, Mark was in the Central Research Department of E. I. du Pont de Nemours and Company (DuPont). Mark performed postdoctoral work at the Massachusetts Institute of Technology and holds a Ph.D. in organic chemistry from Yale University and a B.A. in chemistry from Rutgers University. Mark has published over 75 peer-reviewed scientific manuscripts and is an inventor on 169 issued patents. Mark has received the Pew Scholar Award and is a frequent presenter at conferences on biotechnology, green chemistry, and bio-based chemicals.

Kaspar Evertz, Ph.D.  |  Executive Vice President, Commercial Bio

Kaspar Evertz, Ph.D.

Kaspar has served as our Executive Vice President, Commercial, since April 2014, after serving as senior consultant starting in December 2013. From 2011 to 2013, he was at Ferrostaal AG (GmbH), as Executive Vice President and Managing Director of Industrial Projects. From 2000 to 2011, he was at Basell, which later became LyondellBasell. He held multiple executive roles, most recently as Vice President, Licensing. From 1989 to 2000, he held management, engineering and research roles at BASF and its spinout Elenac.

Kaspar earned a doctorate in chemistry from the University of Konstanz, Germany; served as a research fellow at the California Institute of Technology; and is named on more than 30 patents.

Jeff Lievense, Ph.D.  |  Senior Engineering Fellow Bio

Jeff Lievense, Ph.D.

Jeff has been Senior Engineering Fellow at Genomatica since March 2015; previously, he served as our Executive Vice President, Process Technology, since May 2012. From December 2007 to April 2012, Jeff served at Amyris, most recently as Executive Vice President, Process Development. From 1994 to November 2007, Jeff was Vice President, Technology and Process Development and served in other technology management positions in the Research and Development organization of Tate & Lyle Plc, a global food and agricultural ingredients company. Prior to that, Jeff was Vice President, Research and Operations and President, Bio-Business Incubator of Michigan for Michigan Biotechnology Institute from 1993 to 1994; Director of Chemical Programs and Pathway Engineering for Genencor International from 1990 to 1993; and held various process engineering, research scientist and product management positions at Eastman Kodak Company from 1982 to 1989. Jeff earned a Ph.D. in chemical engineering from Purdue University and a B.S. in chemical engineering from the University of Michigan. He currently serves as an advisor to the Technical University of Delft Process Technology Institute (DPTI), and is a contributing instructor to UCSD’s Microbial Fermentation Workshop.

Nelson Barton, Ph.D.  |  Senior Vice President, Research and Development Bio

Nelson Barton, Ph.D.

Nelson, promoted to Senior Vice President of Research and Development in October 2015, originally joined Genomatica in October 2011 as our Vice President of Research and Development. From 2000 to 2011, Nelson held several roles at Verenium Corporation (formerly Diversa Corporation), including Vice President, R&D from 2008 to 2009, Sr. Vice President, R&D from 2009 to 2010 and Head of R&D starting in 2010 when Verenium’s biofuels business was acquired by BP Biofuels Corporation. From 1996 to 2000, he was Fermentation Scientist and Manager, R&D Biologics with Calbiochem-Novabiochem. Nelson holds a BA in Molecular Biology from University of California, Berkeley and a Ph.D. from University of Miami, School of Medicine. Nelson was a Postdoctoral fellow at Harvard University, Department of Cell and Development Biology and a Howard Hughes fellow at University of California, San Diego, Department of Pharmacology.

Steve Weiss  |  Marketing Bio

Steve Weiss

Steve leads Genomatica’s corporate marketing, and has helped build its high visibility and recognition, while supporting its worldwide strategic partnering program. He has held this role as a consultant since May 2010. His consulting firm, Grey Heron, has worked with multiple cleantech firms including Aspen Aerogels, Icynene and Xicato. Previously, Steve was Vice President, Marketing at Serious Energy from June 2006 to December 2008. Steve has held a variety of technical, marketing and management roles at companies including IBM, HP, Ingres, Central Point Software and CommerceNet. Steve has Masters and Bachelors degrees in Computer Science from MIT.

Damien A. Perriman  |  Vice President, Business Development Bio

Damien A. Perriman

Damien has served as our Vice President, Business Development since November 2010. From February 2009 to November 2010, Damien served as Vice President of Business Development at Verdezyne, Inc., an industrial biotechnology company. From June 2007 to February 2009, Damien served in the Corporate New Ventures and Bioscience unit at Dow, and as deputy commissioner for the Queensland Government Trade Office in Los Angeles from November 2002 to May 2007. Damien holds an M.B.A. from the Anderson Graduate School of Management at the University of California, Los Angeles and a B.S. in Industrial Chemistry from the University of New South Wales.

Cameron Hibbert  |  Vice President, Licensing Bio

Cameron Hibbert

Cameron has served as our Vice President, Licensing, since February 2015. From July 2006 to January 2015, he was at LyondellBasell, most recently as Global Business Manager, Polyolefin Licensing. From June 1997 to July 2006, Cameron held multiple roles at Basell Australia. He received his Bachelor Engineering (Chemical) Honours from Monash University in Melbourne, and an MBA (Honours) from The University of Melbourne.

Joseph P. Kuterbach  |  Vice President, Operations and Technology Transfer Bio

Joseph P. Kuterbach

Joe has served as our Vice President, Operations and Technology Transfer since March 2010. From July 1998 to March 2010, Joe was a manager of process engineering at LyondellBasell Industries N.V., or Lyondell, a petrochemicals company. Before it was acquired by Lyondell, Joe worked at ARCO Chemical Company from June 1980 to July 1998, in research and development, plant technical and operations and process engineering. Prior to that, from June 1976 to June 1980, Joe worked in process engineering at Air Products and Chemicals, Inc., a gas and chemicals company. Joe holds an M.S. in Chemical Engineering from Lehigh University and a B.S. in Chemical Engineering from Drexel University.

Tom McDonald  |  Vice President, Finance Bio

Tom McDonald

Tom joined Genomatica in March 2010 as our senior director of finance, and was promoted to vice president of finance in September 2015. He brings over 20 years of public, private and Big 4 experience.

Prior to Genomatica, he was executive director of finance and controller at Somaxon Pharmaceuticals (SOMX), with direct involvement in their IPO and follow-on debt and equity financings. Previously, he was director of finance and controller at Instromedix, a technology-based manufacturing company. He started his career in audit services at Price Waterhouse.

Tom has a BA in Business Economics from UCLA, and is a Certified Public Accountant. Tom is on the board of directors of Build a Miracle, a non-profit for families in need.